Fol. Biol. 2013, 59, 154-161
https://doi.org/10.14712/fb2013059040154
Serum Levels of Matrix Metalloproteinases 2 and 9 and TGFBR2 Gene Screening in Patients with Ascending Aortic Dilatation
References
1. 1998) Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1. Circulation 98, 249-255.
< , E., Hasenstab, D., Kenagy, R. D., Starcher, B., Clowes, M. M., Clowes, A. W. (https://doi.org/10.1161/01.CIR.98.3.249>
2. 1994) Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ. Res. 75, 539-545.
< , M. P., Zempo, N., Clowes, A. W., Galardy, R. E., Reidy, M. A. (https://doi.org/10.1161/01.RES.75.3.539>
3. 2002) Genetic analysis of the mammalian transforming growth factor-β superfamily. Endocr. Rev. 23, 787-823.
< , H., Brown, C. W., Matzuk, M. M. (https://doi.org/10.1210/er.2002-0003>
4. 2007) Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in the thoracic aortic aneurysm in Marfan syndrome. Circ. Res. 101, 512-522.
< , A. W., Yeung, K., Sandor, G. G., Judge, D. P., Dietz, H. C., van Breemen, C. (https://doi.org/10.1161/CIRCRESAHA.107.157776>
5. 1995) Matrix metalloproteinases and cardiovascular disease. Circ. Res. 7, 863-868.
< , C. M., McEwan, J. R., Henney, A. (https://doi.org/10.1161/01.RES.77.5.863>
6. 2009) New fibrillin gene mutation – possible cause of ascending aortic dilatation in patients with aortic valve disease: Preliminary results. Int. J. Angiol. 18, 99-102.
< , J., Lindner, J., Vaněk, I., Šímová, J., Mazura, I., Miler, I., Čiháková, J., Čapek, P., Belák, J. (https://doi.org/10.1055/s-0031-1278335>
7. 2000) Matrix metalloproteinase expression in nonrheumatic aortic stenosis. Cardiovasc. Pathol. 9, 281-286.
< , M. E., Shirani, J., Wolf, P., Brown, D. L. (https://doi.org/10.1016/S1054-8807(00)00043-0>
8. 2003) Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation. J. Thorac. Cardiovasc. Surg. 126, 797-805.
< , P. W. M., de Sa, M. P. L., Verma, S., Nili, N., Kazemian, P., Butany, J., Strauss, B. H., Weisel, R. D., David, T. E. (https://doi.org/10.1016/S0022-5223(03)00398-2>
9. 1994) Increased expression of matrix metalloproteinases and matrix degrade activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94, 2493-503.
< , Z. S., Sukhova, G. K., Lark, M. W., Libby, P. (https://doi.org/10.1172/JCI117619>
10. 1994) The emerging concept of vascular remodeling. N. Engl. J. Med. 330, 1431-1438.
, G. H., Dzau, V. J. (
11. 2000) Remodeling of carotid artery is associated with increased expression of matrix metalloproteinases in mouse blood flow cessation model. Circulation 102, 2861-2866.
< , D., Ivan, E., Johnson, C., Magid, R., Galis, Z. S. (https://doi.org/10.1161/01.CIR.102.23.2861>
12. 1995) Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 9, 576-596.
< , S. K., Hunter, T. (https://doi.org/10.1096/fasebj.9.8.7768349>
13. 2000) Collagen and elastin degradation by matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase in aortic dissection. Hum. Pathol. 31, 640-646.
< , T., Asuwa, N. (https://doi.org/10.1053/hupa.2000.7642>
14. 2005) Thoracic and abdominal aortic aneurysms. Circulation 111, 816-828.
< , E. M. (https://doi.org/10.1161/01.CIR.0000154569.08857.7A>
15. 2009) Transforming growth factor-β signaling in thoracic aortic aneurysm development: a paradox in pathogenesis. J. Vasc. Res. 46, 119-137.
< , J. A., Spinale, F. G., Ikonomidis, J. S. (https://doi.org/10.1159/000151766>
16. 2005) Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc. Pathol. 14, 80-87.
< , J. J., Dempfle, C.-E., Grobholz, R., Fischer, C. S., Vocke, D. C., Kilic, R., Sarikoc, A., Pinol, R., Hagl, S., Lang, S., Brueckmann, M., Borggrefe, M. (https://doi.org/10.1016/j.carpath.2005.01.002>
17. 2009) Serum levels of matrix metalloproteinases -1, -2, -3 and -9 in thoracic aortic diseases and acute myocardial ischemia. J. Cardiothorac. Surg. 4, 59.
< , G. T., Antonitsis, P., Charokopos, N., Foroulis, C. N., Anastasiadis, K., Rouska, E., Argiriadou, H., Rammos, K., Papakonstantinou, C. (https://doi.org/10.1186/1749-8090-4-59>
18. 2004) Increased tissue microarray matrix metalloproteinase expression favors proteolysis in thoracic aortic aneurysms and dissections. Ann. Thorac. Surg. 78, 2106-2110.
< , G. J., Ravichandran, P., Korkolis, D. P., Rimm, D. L., Elefteriades, J. A. (https://doi.org/10.1016/j.athoracsur.2004.05.088>
19. 2002) Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J. Clin. Invest. 110, 625-632.
< , G. M., Xiong, W., Greiner, T. C., Zhao, Y., Fiotti, N., Baxter, B. T. (https://doi.org/10.1172/JCI0215334>
20. 2009) Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr. Opin. Cell. Biol. 21, 645-653.
< , C. J., Butler, G. S., Rodríguez, D., Overall, C. M. (https://doi.org/10.1016/j.ceb.2009.06.006>
21. 2008) Progress in matrix metalloproteinase research. Mol. Aspects Med. 29, 290–308.
< , G., Nagase, H. (https://doi.org/10.1016/j.mam.2008.05.002>
22. 2003) Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in Marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm. Circulation 108, II 329-II 334.
< , M., West, M., West, J., Summers, K., Walker, P., Nagata, M., Watanabe, T. (https://doi.org/10.1161/01.cir.0000087660.82721.15>
23. 2003) Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nat. Genet. 33, 407-411.
< , E. R., Frischmeyer, P. A., Arking, D. E., Myers, L., Bunton, T. E., Gayraud, B., Ramirez, F., Sakai, L. Y., Dietz, H. C. (https://doi.org/10.1038/ng1116>
24. 2007) Matrix metalloproteinases and the regulation of tissue remodeling. Nat. Rev. Mol. Cell. Biol. 8, 221-833.
< , A., Ewald, A. J., Werb, Z. (https://doi.org/10.1038/nrm2125>
25. 2005) Mutations in transforming growth factor-β receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation 112, 513-520.
< , H., Fadulu, V. T., Chang, J., Lafont, A., Hasham, S. N., Sparks, E., Giampietro, P. F., Zaleski, C., Estrera, A. L., Safi, H. J., Shete, S., Willing, M. C., Raman, C. S., Milewicz, D. M. (https://doi.org/10.1161/CIRCULATIONAHA.105.537340>
26. R Development Core Team (2010) R: A Language and Environment for Statistical Computing, Reference Index Version 2.15.2. Vienna, Austria, R Foundation for Statistical Computing.
27. 2008) Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem. Pharmacol. 75, 346-359.
< , J. D., Khalil, R. A. (https://doi.org/10.1016/j.bcp.2007.07.004>
28. 2000) Mutations in calciumbinding epidermal growth factor modules render fibrillin-1 susceptible to proteolysis: a potential disease-causing mechanism in Marfan syndrome. J. Biol. Chem. 275, 12339-12345.
< , D. P., Ono, R. N., Notbohm, H., Muller, P. K., Bachinger, H. P., Sakai, L. Y. (https://doi.org/10.1074/jbc.275.16.12339>
29. 2000) The molecular genetics of Marfan syndrome and related microfibrillopathies. J. Med. Genet. 37, 9-25.
< , P. N., Godfrey, M. (https://doi.org/10.1136/jmg.37.1.9>
30. 2001) The molecular pathogenesis of the Marfan syndrome. Cell. Mol. Life Sci. 58, 1698-1707.
< , P. N., Booms, P. (https://doi.org/10.1007/PL00000807>
31. 1991) Purification and partial characterization of fibrillin, a cysteine-rich structural component of connective tissue microfibrils. J. Biol. Chem. 266, 14763-14770.
< , L. Y., Keene, D. R., Glanville, R. W., Bachinger, H. P. (https://doi.org/10.1016/S0021-9258(18)98752-1>
32. 1998) Patterns of expression of fibrinolytic genes and matrix metalloproteinase-9 in dissecting aortic aneurysms. Am. J. Pathol. 152, 703-710.
, J., Bordin, G. M., Adar, R., Smolinsky, A., Seiffert, D., Engelberg, I., Dilley, R. B., Thinnes, T., Loskutoff, D. J. (
33. 1998) Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan’s syndrome. Circulation 98 (Suppl), II331-338.
, A. M., Luna, R. E., Horiba, K., Stetler-Stevenson, W. G., McAllister, H. A., Willerson, J. T., Ferrans, V. J. (
34. 2010) Matrix metalloproteinases – an overview. Res. Rep. Biol. 1, 1-20.
, B. S. (
35. Šetina, M., Pirk, J., Holub, J., Fialka, R., Branny, P., Brát, R., Černý, Š., Drašnar, A., Hájek, T., Lindner, J., Lonský, V., Mokráček, A., Němec, P., Straka, Z. (2012) Survey of Selected Cardiac Surgery Operations in the CR, p. 34. ÚZIS ČR, NKCHR, Prague, Czech Republic. (in Czech).
36. 1996) The genomic structure of the gene encoding the human transforming growth factor β type II receptor (TGF-β RII). Genomics 36, 341-344.
< , S., Hagiwara, K., Nagashima, M., Gemma, A., Bennett, W. P., Harris, C. C. (https://doi.org/10.1006/geno.1996.0471>
37. 1997) Mutation analysis of coding sequence of the entire transforming growth factor β type II receptor gene in sporadic human colon cancer using genomic DNA and intron primers. Oncogene 14, 1255-1258.
< , S., Tani, M., Nagashima, M., Hagiwara, K., Bennet, W. P., Yokota, J., Harris, C. C. (https://doi.org/10.1038/sj.onc.1200938>
38. 2000) Atherosclerosis-related aortic dissection. Kyobu Geka 53, 194-201.
, K., Sugisaki, y., Kumazaki, T., Tanaka, S. (
39. 1994) Mechanism of activation of the TGF-β receptor. Nature 370, 341-347.
< , J. L., Attisano, L., Wieser, R., Ventura, F., Massagué, J. (https://doi.org/10.1038/370341a0>
40. 2007) Targeting MMPs in acute and chronic neurological conditions. Neurotherapeutics 4, 580-589.
< , V. W., Agrawal, S. M., Stirling, D. (https://doi.org/10.1016/j.nurt.2007.07.005>
41. 2009) Thoracic aortic dissection: are matrix metalloproteinases involved? Vascular 17, 147-157.
< , X., Ying, H., LeMaire, S. A. (https://doi.org/10.2310/6670.2008.00087>